Company to Present Data on the Use of its Proprietary Technology to Provide Accurate, Fully Automated ECG Analysis for Drug Cardiac Safety at 34th Annual ISCE Meeting
SANTA CLARA, Calif., March 31 /PRNewswire-FirstCall/ -- NewCardio, Inc., a cardiac diagnostic and services company, today announced that senior leadership will present clinical data from two abstracts and discuss applications for its proprietary technology at the 34th Annual International Society for Computerized Electrocardiology (ISCE) Conference. The conference is scheduled from April 23-27, 2009 in Panama City Beach, Florida.
The Society is devoted to the advancement of electrocardiography through the application of computer methods and its annual scientific conference brings together scientists, clinicians, engineers and policy makers working in the field. Dr. Branislav Vajdic, NewCardio’s Chief Executive Officer and Dr. Bosko Bojovic, Co-Founder and Senior Technology Consultant, will present at this conference. Visit http://www.isce.org/generalinfo.html for more information.
Drs. Vajdic and Bojovic will present two abstracts at the conference:
Branislav Vajdic, PhD, NewCardio’s Chief Executive Officer, commented, “NewCardio management is excited to discuss our findings and elaborate on how we can bring new levels of efficiency and accuracy to clinical drug trials with our fully automated QTinno(TM) solution. Unlike other approaches, which are limited due to the reliance on the two-dimensional methodology, NewCardio’s proprietary technology matches the most rigorous manual readings from highly trained cardiologists in a fully automated manner. The ISCE Conference is an excellent opportunity to discuss our novel technology with recognized industry leaders in attendance, and explore the various applications we will be aggressively pursuing in the coming months and years.”
About NewCardio, Inc.
NewCardio is a cardiac diagnostic and services company focused on the development of a proprietary platform technology to provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio’s development-stage software and hardware products and services are intended to improve the diagnosis and monitoring of cardiovascular disease (CVD), as well as cardiac safety assessment of drugs under development. NewCardio’s three-dimensional ECG platform is designed to reduce the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. For more information, visit www.newcardio.com.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2008 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.
To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0
CONTACT: Investors, Jeff Stanlis, Partner and Vice President of
Communications of Hayden IR, +1-602-476-1821, jeff@haydenir.com, for
NewCardio, Inc.
Web site: http://www.newcardio.com/
